Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study

Author(s):

Gabriel Pardo, MD, FAAN,Martin Belkin, DO

Key Takeaways

Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Further research is needed to fully understand the mechanisms and extent of cognitive benefits provided by DMTs.

Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.

EP: 1.The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

EP: 2.Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024

EP: 3.Biomarkers and Therapeutic Impact on PIRA

EP: 4.Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data

EP: 5.Addressing PIRA in Clinical Practice and Patient Conversations

EP: 6.Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits

Now Viewing

EP: 7.Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study

Video content above is prompted by the following:

Cognition data was examined in the CLARIFY-MS extension study in patients 4 years after initial dose of cladribine. Please discuss changes in Symbol Digit Modalities Test (SDMT) scores over time and what these results mean for the cognitive function of the patient.
What are your impressions of long-term cognition data with other high-efficacy therapies?
- How do you utilize cognitive data in your practice?